- Report
- November 2023
- 276 Pages
Global
From €9227EUR$9,500USD£7,960GBP
- Report
- November 2023
- 353 Pages
Global
From €9227EUR$9,500USD£7,960GBP
- Report
- January 2021
- 900 Pages
United States
From €3205EUR$3,300USD£2,765GBP
- Report
- April 2023
- 180 Pages
Global
From €7284EUR$7,500USD£6,284GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2671EUR$2,750USD£2,304GBP
- Report
- April 2023
- 120 Pages
Global
From €4614EUR$4,750USD£3,980GBP
- Report
- May 2021
- 50 Pages
China
From €2525EUR$2,600USD£2,178GBP
- Report
- January 2019
- 35 Pages
Global
From €971EUR$1,000USD£838GBP
Ibrance is a type of breast cancer drug used to treat certain types of breast cancer in postmenopausal women. It is a type of hormone therapy, which works by blocking the action of the hormone estrogen in the body. Ibrance is used in combination with other drugs, such as letrozole, to treat advanced or metastatic breast cancer. It is also used to reduce the risk of recurrence in women who have already been treated for early-stage breast cancer.
Ibrance is a relatively new drug, having been approved by the US Food and Drug Administration in 2015. It is a targeted therapy, meaning it works by targeting specific molecules in the body that are involved in the growth and spread of cancer cells.
Ibrance is marketed by Pfizer, Inc., and is available in both tablet and capsule form. Other companies in the market include Novartis, AstraZeneca, and Eli Lilly. Show Less Read more
